Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
10.3346/jkms.2016.31.7.1160
- Author:
Seung Shin LEE
1
;
Sung Hoon JUNG
;
Jae Sook AHN
;
Yeo Kyeoung KIM
;
Min Seok CHO
;
Seung Yeon JUNG
;
Je Jung LEE
;
Hyeoung Joon KIM
;
Deok Hwan YANG
Author Information
1. Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea. drydh1685@hotmail.com
- Publication Type:Brief Communication ; Case Reports
- Keywords:
Peripheral T Cell Lymphoma;
Pralatrexate;
Bortezomib;
Elderly
- MeSH:
Aged;
Aminopterin/adverse effects/*analogs & derivatives/therapeutic use;
Antineoplastic Agents/adverse effects/*therapeutic use;
Bortezomib/adverse effects/*therapeutic use;
Drug Administration Schedule;
Drug Therapy, Combination;
Humans;
Lymphoma, T-Cell, Peripheral/diagnostic imaging/*drug therapy/pathology;
Male;
Neoplasm Recurrence, Local;
Neutropenia/etiology;
Positron Emission Tomography Computed Tomography
- From:Journal of Korean Medical Science
2016;31(7):1160-1163
- CountryRepublic of Korea
- Language:English
-
Abstract:
Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities, and poor functional status. Thus, treatment of elderly patients with relapsed or refractory PTCL remains a challenge for clinicians. A recent study disclosed that pralatrexate has a synergistic effect in combination with bortezomib. Weekly pralatrexate and bortezomib were administered intravenously for 3 weeks in a 4-week cycle. Of 5 patients, one achieved complete response after 4 cycles which has lasted 12 months until now. Another patient attained partial response after 2 cycles. Only 1 patient experienced grade 3 thrombocytopenia and neutropenia. Two patients suffered from grade 3 mucositis. Combination therapy with pralatrexate and bortezomib may be used as a salvage therapy for relapsed or refractory PTCL in the elderly with a favorable safety profile.
